ODTX (Odyssey Therapeutics) Tax Provision: $-0.06 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ODTX Odyssey Therapeutics Inc ODTX
13 GF Score
Price $26.49
! 2 Warning Signs
View Full Analysis

What is Odyssey Therapeutics Tax Provision?

Odyssey Therapeutics ODTX +6.93% 13 Tax Provision is $-0.06 Mil as of Jun. 2026. GuruFocus rates ODTX with a GF Score™ of 13/100. The stock has 2 warning signs investors should review.

Odyssey Therapeutics's tax provision for the three months ended in Jun. 2026 was $0.01 Mil. Its tax provision for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.06 Mil.

Odyssey Therapeutics Tax Provision Historical Data

* Premium members only.

The historical data trend for Odyssey Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Odyssey Therapeutics Tax Provision Chart

Odyssey Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Tax Provision
-0.35 -0.45 -0.47 0.93

Odyssey Therapeutics Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Jun25 Dec25 Mar26 Jun26
Tax Provision Get a 7-Day Free Trial Premium Member Only -0.14 -0.03 0.00 -0.06 0.01
ODTX
13GF Score
Odyssey Therapeutics Inc ODTX
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Odyssey Therapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of $-0.06 Mil mean?
Odyssey Therapeutics (ODTX) has a Tax Provision of $-0.06 Mil as of Jun. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Odyssey Therapeutics and its competitors.
Is Odyssey Therapeutics' Tax Provision too high?
Odyssey Therapeutics' current Tax Provision is $-0.06 Mil. Overall, Odyssey Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Odyssey Therapeutics' Tax Provision compare to SANA and GERN?
Odyssey Therapeutics' Tax Provision of $-0.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Odyssey Therapeutics and its competitors. Odyssey Therapeutics's current Tax Provision is $-0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Odyssey Therapeutics stock overvalued right now?
Odyssey Therapeutics (ODTX) has a current Tax Provision of $-0.06 Mil. The current Tax Provision is $-0.06 Mil. Odyssey Therapeutics' overall GF Score™ is 13/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Odyssey Therapeutics (ODTX), the current Tax Provision is $-0.06 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Odyssey Therapeutics Business Description

Address 51 Sleeper Street, Boston, MA, USA, 02210
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
13GF Score

Get the complete analysis for ODTX

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.49
Price